This account will no longer be active or monitored.
We welcome our community to follow @ACSPublications or sign up for e-Alerts for future updates from ACS Chemical Neuroscience: https://t.co/2YP9JoWknm
Don't miss out on this exciting discussion!
This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy
Read the latest research ➡ https://t.co/8SGqAqQUvS
Next week is World #AntimicrobialResistance Awareness Week! Join us for a webinar discussing the cutting edge work being done to fight multi-drug resistant bacteria. 🦠
📅 Wed Nov 20, 11am EST.
Register here ➡️ https://t.co/0kTIScijga
Don't miss out on this exciting discussion!
This collection from #ACSChemNeuro dives into the research around #MDMA as a potential breakthrough therapy
Read the latest research ➡ https://t.co/wmjYLLUvGX
❗ LAST CALL! Call for Papers: ACS Pharmacology and Translational Science invites submissions for a Virtual Special Issue on new perspectives and advances in translational #pain research to treat pain.
Submit papers by August 1, 2024 ➡ https://t.co/b1ckrTbQOS
I am proud to have collaborated with @cahhcardi et al in this amazing paper now published in @ACSChemNeurosci.
Link: https://t.co/yBz31czQLs
@Ariel_Lab
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ https://t.co/r3t26W1ZWN
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ https://t.co/yjAGOUF5g8
Read our latest review on the gut-microbiome brain axis in Parkinson’s disease and role of “biotics” approach #neuroscience#gutmicrobiota@ACSChemNeurosci https://t.co/xJUKKZkRIb
📢Stay up to date with the latest📢 This new collection of #ACSChemNeuro research joins the discussion around #MDMA as a potential breakthrough therapy
Read the latest research ➡ https://t.co/PiwSg7FvIJ
To sum up today's adcomm: While the experts saw potential in the use of MDMA-assisted therapy in the treatment of PTSD, there were too many confounding variables and possible safety concerns to push for approval #Lykos
Fascinating discussions online today surrounding the FDA's consideration of a new #MDMA treatment for PTSD 🤔
When is a double-blinded study not enough? How can you blind for a treatment that includes such pronounced and well-known effects?
Let us know what you think! ⬇
📢New collection of #ACSChemNeuro research as the FDA is expected to announce a decision on a new treatment involving #MDMA today ⏰
Read the latest research ➡ https://t.co/MiFPxVyOnt
It's all things adamantane in our (@Lambert_Usyd) latest synthetic cannabinoid work, out now in @ACSChemNeurosci!
We synthesised and evaluated a library of adamantane-derived SCRAs, including fluorinated and deuterated analogues 🧪
🧵
https://t.co/yq4EPZPvyZ
This study builds on our @ACSChemNeurosci paper last year, where @PashaDavoudian mapped c-Fos response in the brain after psilocybin or ketamine, identifying the list of shared and distinct brain regions impacted by the drugs
https://t.co/dyi5CWqLoZ